{"disease":{"id":"myelosuppression","name":"myelosuppression"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03846414","title":"Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06641934","title":"Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT03126890","title":"Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03740464","title":"Long-acting G-CSF for Febrile Neutropenia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":556,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04607668","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":326,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04905329","title":"A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations","phase":"","overall_status":"UNKNOWN","enrollment_count":285,"lead_sponsor_name":"Moscow Clinical Scientific Center","has_results":false},{"nct_id":"NCT05780294","title":"A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06665737","title":"Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Department of Medical Services Ministry of Public Health of Thailand","has_results":false},{"nct_id":"NCT03793205","title":"G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04887831","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06490081","title":"Trilaciclib Prevents Myelosuppression With Chemoradiotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05442177","title":"Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity","phase":"","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Taichung Tzu Chi Hospital","has_results":false},{"nct_id":"NCT06699472","title":"A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03974516","title":"Careseng 1370 for Healthy Volunteers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"i Cure Biotech Co., Ltd.","has_results":true},{"nct_id":"NCT05622058","title":"A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Aileron Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04504513","title":"Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}